Published on 29 Jul 2022 on Zacks via Yahoo Finance
AstraZeneca’s AZN second-quarter 2022 core earnings of 86 cents per American depositary share (ADS) beat the Zacks Consensus Estimate of 78 cents. Core earnings of $1.72 per share rose 92% year over year on a reported basis and 89% at constant exchange rates (CER).
Total revenues were $10.77 million, up 31% on a reported basis and 37% at CER to $10.77 billion in the quarter, driven by higher product sales. Revenues beat the Zacks Consensus Estimate of $10.435 billion.
All growth rates mentioned below are on a year-over-year basis and at CER.